- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Aktis Oncology, Inc. Common stock(AKTS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for AKTS
11/13/2026: AKTS (1-star) is currently NOT-A-BUY. Pass it for now.
Aktis Oncology is a clinical-stage biotechnology company developing targeted alpha radiopharmaceuticals utilizing proprietary miniprotein platforms for solid tumor cancers. The company's primary strengths include its innovative targeting technology, robust financial backing from pharmaceutical partners, and a strengthened balance sheet following its recent public debut. Its core investment story centers on advancing clinical candidates like AKY-1189 through key trial milestones to address large oncology markets. Key risks involve pre-commercial financial losses, trial execution uncertainties, and intense competition within precision oncology. The stock suits growth-oriented investors comfortable with high volatility and clinical-stage risk, who should closely monitor upcoming trial readouts and partnership developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers high-growth potential driven by innovative clinical-stage radiopharmaceutical platforms addressing large oncology markets. |
| Momentum investor | Strong fit while signal remains positive | Stock price movement is highly sensitive to clinical trial data readouts and partnership announcements. |
| Value investor | Weak fit | The absence of commercial revenue and ongoing clinical losses make traditional valuation metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends, focusing entirely on reinvesting capital into drug development. |
| Low-risk investor | Weak fit | High clinical development risks and share price volatility present significant risk exposure for conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotechnology stocks frequently experience sharp price swings around data releases and market sentiment shifts. |
| Valuation risk | Medium / high | Valuation relies heavily on future clinical success and pipeline commercialization potential rather than current earnings. |
| Competition risk (radiopharmaceutical and targeted oncology competition) | High | The company faces intense competition from established pharmaceutical giants and alternative cancer-targeting drug modalities. |
| Business quality | Medium | The science and proprietary miniprotein platform are promising, but the business model remains pre-revenue. |
| Dividend income | Low / none | No dividend is paid or anticipated in the near term. |
| Execution risk | High | Success depends entirely on executing complex clinical trials and achieving positive regulatory and efficacy milestones. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 927.36M USD | Price to earnings Ratio - | 1Y Target Price 35.88 |
Price to earnings Ratio - | 1Y Target Price 35.88 | ||
Volume (30-day avg) 360.6K shares | Beta - | 52 Weeks Range 13.96 - 34.19 | Updated Date 11/15/2026 |
52 Weeks Range 13.96 - 34.19 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.7 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -8.12% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Therapeutic R&D and Strategic Collaborations | Upfront license fees, research funding, and milestone payments from partnerships such as the collaboration with Eli Lilly. | The company currently operates pre-revenue, generating financial support from partnership deals and equity financing rather than product sales. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 420.16M | Price to Sales(TTM) 74.87 |
Enterprise Value 420.16M | Price to Sales(TTM) 74.87 | ||
Enterprise Value to Revenue 41.77 | Enterprise Value to EBITDA - | Shares Outstanding 53.93M | Shares Floating 28.49M |
Shares Outstanding 53.93M | Shares Floating 28.49M | ||
Percent Insiders 14.21 | Percent Institutions 78.1 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

